BACKGROUND: Hyperkalemia is common in patients receiving maintenance hemodialysis. However, few studies have examined the association between serum potassium level and mortality. METHODS: This study used annual cohorts of hemodialysis patients during 2007-2010. To determine hyperkalemia prevalence, monthly hyperkalemia was defined as serum potassium level ≥5.5 mEq/l; prevalence was calculated as a ratio of hyperkalemia episodes to follow-up time, reported separately by long and short interdialytic interval. To determine the impact of hyperkalemia on mortality, patients in the 2010 cohort were followed from first potassium measurement until death or a censoring event; hyperkalemia was defined, sequentially, by potassium levels 5.5-6.0 mEq/l at 0.1 mEq/l intervals. Time-dependent Cox proportional hazards modeling was used to estimate the association between hyperkalemia and mortality. RESULTS: The 4 annual cohorts ranged from 28,774 to 36,888 patients. Mean age was approximately 63 years, about 56% were men, 51% were white and 44% had end-stage renal disease caused by diabetes. Hyperkalemia prevalence was consistently estimated at 16.3-16.8 events per 100 patient-months. Prevalence on the day after the long interdialytic interval was 2.0-2.4 times as high as on the day after the short interval. Hyperkalemia, when defined as serum potassium ≥5.7 mEq/l, was associated with all-cause mortality (adjusted hazards ratio (AHR) 1.13, 95% CI 1.01-1.28, p = 0.037, vs. <5.7 mEq/l) after adjustment. AHRs increased progressively as the hyperkalemia threshold increased, reaching 1.37 (95% CI 1.16-1.62, p < 0.0001) for ≥6.0 mEq/l. CONCLUSIONS: The long interdialytic interval was associated with increased likelihood of hyperkalemia. Hyperkalemia was associated with all-cause mortality beginning at serum potassium ≥5.7 mEq/l; mortality risk estimates increased ordinally through ≥6.0 mEq/l, suggesting a threshold at which serum potassium becomes substantially more dangerous.
BACKGROUND:Hyperkalemia is common in patients receiving maintenance hemodialysis. However, few studies have examined the association between serum potassium level and mortality. METHODS: This study used annual cohorts of hemodialysis patients during 2007-2010. To determine hyperkalemia prevalence, monthly hyperkalemia was defined as serum potassium level ≥5.5 mEq/l; prevalence was calculated as a ratio of hyperkalemia episodes to follow-up time, reported separately by long and short interdialytic interval. To determine the impact of hyperkalemia on mortality, patients in the 2010 cohort were followed from first potassium measurement until death or a censoring event; hyperkalemia was defined, sequentially, by potassium levels 5.5-6.0 mEq/l at 0.1 mEq/l intervals. Time-dependent Cox proportional hazards modeling was used to estimate the association between hyperkalemia and mortality. RESULTS: The 4 annual cohorts ranged from 28,774 to 36,888 patients. Mean age was approximately 63 years, about 56% were men, 51% were white and 44% had end-stage renal disease caused by diabetes. Hyperkalemia prevalence was consistently estimated at 16.3-16.8 events per 100 patient-months. Prevalence on the day after the long interdialytic interval was 2.0-2.4 times as high as on the day after the short interval. Hyperkalemia, when defined as serum potassium ≥5.7 mEq/l, was associated with all-cause mortality (adjusted hazards ratio (AHR) 1.13, 95% CI 1.01-1.28, p = 0.037, vs. <5.7 mEq/l) after adjustment. AHRs increased progressively as the hyperkalemia threshold increased, reaching 1.37 (95% CI 1.16-1.62, p < 0.0001) for ≥6.0 mEq/l. CONCLUSIONS: The long interdialytic interval was associated with increased likelihood of hyperkalemia. Hyperkalemia was associated with all-cause mortality beginning at serum potassium ≥5.7 mEq/l; mortality risk estimates increased ordinally through ≥6.0 mEq/l, suggesting a threshold at which serum potassium becomes substantially more dangerous.
Authors: Conner D Galloway; Alexander V Valys; Jacqueline B Shreibati; Daniel L Treiman; Frank L Petterson; Vivek P Gundotra; David E Albert; Zachi I Attia; Rickey E Carter; Samuel J Asirvatham; Michael J Ackerman; Peter A Noseworthy; John J Dillon; Paul A Friedman Journal: JAMA Cardiol Date: 2019-05-01 Impact factor: 14.676
Authors: Steven Fishbane; Martin Ford; Masafumi Fukagawa; Kieran McCafferty; Anjay Rastogi; Bruce Spinowitz; Konstantin Staroselskiy; Konstantin Vishnevskiy; Vera Lisovskaja; Ayman Al-Shurbaji; Nicolas Guzman; Sunil Bhandari Journal: J Am Soc Nephrol Date: 2019-06-14 Impact factor: 10.121
Authors: Amelie Bernier-Jean; Germaine Wong; Valeria Saglimbene; Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Vanessa Garcia-Larsen; David W Johnson; Marcello Tonelli; Jörgen Hegbrant; Jonathan C Craig; Armando Teixeira-Pinto; Giovanni F M Strippoli Journal: Clin J Am Soc Nephrol Date: 2021-12-01 Impact factor: 8.237
Authors: Amanda J Vinson; Wayel Zanjir; Megi Nallbani; Judah Goldstein; Janel Swain; David A Clark; Keigan M More; John R Manderville; Patrick T Fok; Hana Wiemer; Karthik K Tennankore Journal: Kidney360 Date: 2022-02-09
Authors: Sehoon Park; Seon Ha Baek; Sung Woo Lee; Anna Lee; Ho Jun Chin; Ki Young Na; Yon Su Kim; Dong-Wan Chae; Jin Suk Han; Sejoong Kim Journal: Sci Rep Date: 2017-05-25 Impact factor: 4.379